ケイセントラ_製品情報概要_H1-4_収載_新発売

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "ケイセントラ_製品情報概要_H1-4_収載_新発売"

Transcription

1 DIC

2 CONTENTS K KVKA K K VKA VKA K - PT-INR KC S 1996VKA VKA 3 KK CS K VKA 12VKAFDA Kcentra in vitro VKA PT-INR CSL214 VKA PT-INRVKA PT-INR K

3 IU 1. K CS PCC Prothrombin Complex Concentrate p p K 4 4-Factor PCC p12 29 HBsHCVHIV-1HIV-2 HIV-1 HBV HCV HAVNAT B19 NAT p % PT-INR 2.9% % 1 DIC p8 3 DIC IU 2 4 3IU 4 8mg 8 4IU 6 12mg 45 92mg 2mL 1 1 1,IU 2 8 6IU 8 16mg 16 8IU 12 24mg mg 4mL C S 2 3p9 3 5

4 2 ph K HIT heparin-induced thrombocytopenia p7 3 B19 4 B19 2 PT-INR kg 25IU/kg 35IU/kg 5IU/kg 1kg 25IU 35IU 5IU 1HBsHCVHIV-1 HIV-2 HIV-1 HBV HCVHAV NAT B19 NAT K 6 1 B19 2 vcjd vcjd HIT heparin-induced thrombocytopenia 6 7

5 % PT-INR 2.9% % % 2 3DIC DIC 2.5% 7 DIC /1 p IU/kg/21IU/ / B

6 5/

7 p PT-INR1.3 KVKA VKA PT-INR VKA PT-INR Day45 K PT-INR IU/kg kg1kg 5,IU 3 PT-INR 1 2 PT-INR PT-INR 24 modified Rankin Scale mrs Day45 predicted blood loss PBL actual blood loss ABL Day14 Day45 FAS PT-INR / Kaplan-MeierPT-INR CT2% / 2 1% packed red blood cells PRBC 8 1g/dL 8 1g/dLPRBC / PRBC / CT2%35% / 2 1%2PRBC8 1g/dL 8 1g/dLPRBC 2 / PRBC 4 / 1 4 / CT35% / 2 2% PRBC8 1g/dL 8 1g/dLPRBC 2 / PRBC 1 24 /PRBC 11g/dL 3% 24/ 2 /% 12 13

8 3 PT-INR 11PT-INR % PT-INR PT-INR Mean SD 3PT-INR Mean SD n=6 n=5 n= PT-INR PT-INR PT 1 PT-INR PT-INR PT Preferred term 23PT-INR 1.3PT-INR PT-INR 1.3PT-INR PT-INR PT-INR 3PT-INR PT-INR PT-INR PT-INR 1 PT-INR

9 PT-INR PT-INR % 24PT-INR PT-INR 1.3PT-INR 31.3 PT-INR n= Day43 n= n= n=4 1 3PT-INR 1 PBL ABL ABLPBL PBL Predicted blood loss 2 ABL Actual blood loss mL 83.3% 5/6 1% 5/5 18.2% 2/111 2 PBL 1 mln= ABL 2 mln= mrsday mrs5 Day454 1 mrs2 Day

10 KVKAK CS VKA CS Intention-to-treatITT-E Intention-to-treatITT-S PT-INR Day9K K PT-INR 1 IU/kg 1 ml/kg mL 25IU 24 PT-INR PT-INR packed red blood cells PRBC PRBC1 24 /PRBC Day45 PT-INR 95% Farrington and Manning 1% 95% 1% 3/ Cochran-Mantel-Haenszel PT-INR 3 ITT-E 1 1kg1kg 2 3PT-INR PT-INRPT-INR / CT2% 3/ % PRBC 8 1g/dL 8 1g/dLPRBC / CT2%35% 3/ %2PRBC8 1g/dL 8 1g/dLPRBC 2 / 3 4 / 1 4 / CT35% 3/ % PRBC8 1g/dL 8 1g/dLPRBC 2 / 3 CT 1% / 2 24 /PRBC 11g/dL 3% 3PRBC PRBC 11g/dL 3% 24 / 18 19

11 % 65.4%7.1% 95%5.8, %1% %67.3%6.2% 95% 6.5, %1% % n= ,19.9 n=14 95 % n=98 95Farrington and Manning ,18.8 n= Farrington and Manning PT-INR PT-INR 3PT-INR %9.6% 52.6% 95% 39.4, % 1% PT-INR / % 3.52,11.9 % 1 8 PT-INR n=98 95Farrington and Manning , n=14 95 PT-INR PT-INR PT-INR % PT-INR PT-INR PT-INR 88%58% PT-INR n=98 n=14 Kaplan-Meier

12 PT-INR 3 12 PT-INR 5 n=98 n=14 4 p<.5 Wilcoxon 3 2 PT-INR 1 PRBC PRBC1 PRBCMean SD Wilcoxon PRBC149% 48/9845% 47/14 PRBC 1 1g/dL3% 24 /PRBC BL PRBC/ Mean SD Wilcoxon Day45 Day45 95 Day45 / %.66,5.5 ITT-S %96% ITT-S n=13 n=19 PT-INR IU/kg mL/kg 1.4mL/kg 2.mL/kg n % mL25IU ITT-S n= ml IU/ ml/ IU/kg ml/kg ml/kg n % n= Mean SD 64.1% 66/ % 71/19 9.7% 1/ % 23/19 PT-INR21.9% 3 2.8% 1.9% 2/13 3.7% 4/

13 KVKAK CS VKA CS Intention-to-treatITT-E Intention-to-treatITT-S PT-INR Day9K K PT-INR mL 25IU 1 IU/kg ml/kg PT-INR 3 PT-INR 24packed red blood cells PRBC 24 PRBC PT-INR 12 95% Newcombe-Wilson 1% 95% 1% PT-INR 4 ITT-E 1actual blood loss:ablpredicted blood loss:pbl5ml / PRBC ABLPBL 2% PRBC ABLPBL 2%3% / ABL PBL 3% PRBC PRBC / ABL PBL 3% ABL PBL/ 2 ABLPBL5mL / ABL PBL/ PRBC ABL PBL 2 PRBC ABLPBL 2% / PRBC PRBC / 1 1kg1kg FDA 33PT-INR PT-INRPT-INR 24 25

14 89.7% 75.3%14.3% 95% 2.8, % 1% PT-INR PT-INR PT-INR % PT-INR PT-INR PT-INR 87%48% 95Newcombe-Wilson% n= , n= PT-INR n=87 n= Kaplan-Meier PT-INR PT-INR 3PT-INR %9.9% 45.3% 95% 31.9, % 1% PT-INR 3 24 PT-INR % 1 8 PT-INR , PT-INR n=87 n=81 p<.5 Wilcoxon n=87 95Newcombe-Wilson 9.9 n=81 BL

15 55.749/ /88 9.1% 8/88 17.% 15/ % 3/ % 11/ % 3/88 3.4% 3/ Day PRBC PRBC 16.1% 14/8714.8% 12/81 Fisher ITT-S %98% PRBC PRBC PRBC Wilcoxon ITT-S 1mL25IU Mean SD n=88 PT-INR IU/kg mL/kg 1.4mL/kg 2.mL/kg ml/kg n % n % n=88 ITT-S ml IU/ ml/ IU/kg ml/kg n= n=

16 % PT-INR 2.9% % PT-INR PT-INR 32 n= % 3 2.9% 1 1.% 1 1.% 1 1.% 5 4.9% 2 1.9% 1 1.% 1 1.% 1 1.% 1 1.% 1 1.% 2 1.9% 1 1.% 1 1.% 1 1.% 1 1.% 1 1.% 1 1.% 8 9.1% 2 2.3% 2 2.3% 2 2.3% 3 3.4% 33 n= n= n= MedDRA Ver / MedDRA Ver / MedDRA / J Ver.18. n= IU/kg 5 Cmax Cmax 162%S 278%Ct1/ CS Mean SD % C S

17 C S , , , , , , IVR9% 2 IVR3 IU/kg IVRt1/2 CmaxAUC CLMRTVss IVRIU/dL / IU/kg 2 t1/2 hn=14 t1/2 h Cmax % AUC kg h/dl CL ml/ kg h MRT h Vss ml/kg IVRIU/dL / IU/kg 2 t1/2 h Cmax % AUC kg h/dl CL ml/ kg h MRT h Vss ml/kg IVRIU/dL / IU/kg 2 t1/2 hn=12 t1/2 h Cmax % AUC kg h/dl CL ml/ kg h MRT h Vss ml/kg IVRIU/dL / IU/kg 2 t1/2 h Cmax % AUC kg h/dl CL ml/ kg h MRT h Vss ml/kg IVRIU/dL / IU/kg 2 t1/2 hn=12 t1/2 h Cmax % AUC kg h/dl CL ml/ kg h MRT h Vss ml/kg IVRIU/dL / IU/kg 2 t1/2 h t1/2 h Cmax % AUC kg h/dl CL ml/ kg h MRT h Vss ml/kg 2 K34 1 K 3IVR IU/dL / IU/kg IU/dL / IU/kg.868 IU/dL / IU/kg IU/dL / IU/kg 3 CS n=6 n=5 C S %normal 3 %normal %normal 3 %normal CS IVRIVR 1 IVRIU/dL / IU/kg= IU/dL/ IU/kg 2IVR % = 1 / IVR n=6 n=5 C S IVR 1 [IU/dL]/[IU/kg] IVR 2 % IVR 1 [IU/dL]/[IU/kg] IVR 2 %

18 3 KK CS 33 3 K CS 3 5% p.5 Wilcoxon36 24 CS BL n=87 n=81 BL n=87 n=81 BL C n=87 n=81 2 n=87 n=81 BL n=87 2 n=87 n=81 n=81 BL BL S C S C S 34 35

19 K K in vitro 6 PCC rf a PT PCC PT PT in vitro PT-INR PCC U/mL rf a nm Marcumar 2.5mg/kg PCC 5U/kg rf a 1 g/kg 15 PTaPTT PT PCCrF a p.5 Wilcoxon PT PCCrF apcc appt p.1 Wilcoxon PT aptt aptt aptt vs F a vs PCC F a vs PCC aptt p , , , aptt 48 aptt vs F a vs PCC F a vs PCC aptt p , , , PT-INR3.6in vitro nm PT-INR3.6 PCC.72U/mL PT-INR3.6 PCC.4U/mL PT-INR3.6 PCC.2U/mL PT-INR3.6 rf a 6nM PT-INR3.6 PT PT L1 1 vs F a vs PCC F a vs PCC PT p , , , p 3 2 vs F a , vs PCC , F a vs PCC , PT PT L 15 1 vs F a vs PCC F a vs PCC vs F a vs PCC F a vs PCC PT p , , , p , , , n=5 rf a (n=5) PCC (n=5) n=5 rf a (n=5) PCC (n=5) 1 PT aptt 2 95Hodges-Lehmann 3 Wilcoxon 36 37

20 8 35IU/kg IU/animal 9 1 IU/kg IU/kg 2IU/kg IU/kg IU/kg 2646 g/kg 3 NOAEL1IU/kg

21 / / % 5%RH 4 2 C 75 5%RH 25 6%RH lux 2W hr/m 2 C S mL mL AMX AMX

22 / Tanaka K.A., et al.: Thromb Res. 122, 117, 28 7 Dickneite, G: Thromb Res. 119, 643, CSL CSL

152273335 1 123 11531 2 5 24 31 2 154301482 1551 JAS 100 2000 105 1101 1 2JAS 1-2 1

152273335 1 123 11531 2 5 24 31 2 154301482 1551 JAS 100 2000 105 1101 1 2JAS 1-2 1 152273335 1 123 11531 2 5 24 31 2 154301482 1551 JAS 100 2000 105 1101 1 2JAS 1-2 1 JAS 1-2 1-2 112 13 1-11-13 100870mg 100830mg11000 1100020.002 2 50 100 2 100 500 2 100 109252165 4514782 7 2.0kg 2-19220.05kg0.2kg

More information

23 3 11 14 46 9.0 7 10m 40.1m 15,883 2,681 25 4 10 39 40 800 180 24 2425 22 21 24 5 3 21 24 10,899 20,472 13,723 33,007 667 400 79,167 8,620 11,694 10,089 25,131 690 215 56,439 13,614 20,897 15,200 32,213

More information

家庭系パソコンの回収再資源化にかかる論点

家庭系パソコンの回収再資源化にかかる論点 1 134 1212 134 2 1 137 1212 (1) 12 12,102 40.2 4,865 2-1 12 21,497 2-2 50.1 2-3 1 kg 2 12 2-1 13 12% 2-1 (2) 2-2 4 4 7 2-3 4 (3) 13.8 2-4 46 10 80 3 3 4 3 2-5, 2-6 13 9 2-7 18 2 2 8 5,000 30 25% 25 2 2

More information

untitled

untitled - 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - - 20 - - 21 - - 22 - - 23 - - 24 - - 25 - - 26 - - 27 - - 28 - - 29 - - 30 -

More information

橡アロマセラピー症状別処方例.PDF

橡アロマセラピー症状別処方例.PDF 1 1 92 E 100ml 1 2 2 1 93 0.5m 10ml 100ml 1 2 3 2 52 0. l 2 4 3 27 3 1 1 3 3 4 5 3 2g 2 3 1 1 1 10ml 3 4 6 3 29 2 2 2 10ml 3 3 4 7 3 30 2 1 2 10ml 3 3 4 8 3 31 1 1 1 1 3 60 10 10 3 2 4 10ml A 2 3 61 20

More information

橡サプリメント.PDF

橡サプリメント.PDF Vol.13,No.1,2004 1 Feb.200Vol.13 No.1 Vol.13,No1,2004 2 70) ph H2 P450 P450 70) Vol.13,No.1,2004 ALDH N- H2 P-450 H2 ADH ADH ADH CYP ADH 200mg/dl ADH P-450CYP CYP CYP 17)18) N- 1 48g ADH 3 Vol.13,No1,2004

More information

2009 Aida et al. Caries Res 2006;40 2000 100 % 78.7 88.0 96.6 98.8 98.8 98.8 100.0 100.0 100 75 69.4 50 75.3 74.8 73.3 73.1 73.0 72.4 71.8 71.7 51.7 40.2 69.4 68.8 73.6 25 22.3 32.8 21.9 22.9 22.1

More information

薬局におけるインシデント事例の集計・分析結果

薬局におけるインシデント事例の集計・分析結果 13 11 14 31 13 11 14 31 13 11 14 31 10 13 13 e-mail 18 4,000 13 14 H13.4.1 11.17 11.18 H14.3.31 13 14 31-1- 600 400 (18.4 17.7 17.0 16.0 15.2 8.2 1.0 2 11 10 12 15 3 1015203040 69.5 7.8 22.7 4 (42.5) 34.3

More information

untitled

untitled ---------- - 1 - ----- 1 Q1 5 Q2 5 Q3 5 Q4 6 Q5 6 Q6 7 Q7 7 Q8 7 Q9 8 Q10 : 8 10 Q1 10 Q2 11 Q3 11 12 Q4 12 Q5 HBs HBc _12 Q6 HBe 12 Q7 13 Q8 NAT 15 Q9 15 Q10 15 Q11 HBs 16 Q12 HBV DNA 16 Q13 17-2 - Q14

More information

橡DI月報200.PDF

橡DI月報200.PDF 2004.3.2 DI 22-2668 15 10 WHIWomen s Health Initiative 15 8 Million women study HRT :1.24 2 1 :1.45 14 :1.74 59 :2.17 10 :2.31 HRT 1 :1.81 HRT :1.31 HRT 65 :2.05 CKCPK http://www.pharmasys.gr.jp http://www.mhlw.go.jp

More information

医薬品リスク管理計画書

医薬品リスク管理計画書 2.5 mg 3.75 mg 5 mg 20mg RMP 2.5 mg 3.75 mg 5 mg 20mg 87339 28 6 1.1 4 8 10 5 8 10 5 TTP 9 梗 6 TIA 11 6 1.2 11 CABG 12 12 13 13 15 2.5mg 15 2. 16 3. 16 4. 19 19 19 18 RMP 28 6 3 5 1 27 8 25 26 3 24 87339

More information

日本化学療法学会雑誌第51巻第2号

日本化学療法学会雑誌第51巻第2号 piperacillin piperacillin PIPC. g Cmax CL PIPC CL CLR CLNR CL PIPC g g Cmax PIPC Key words: piperacillin Piperacillin PIPC PIPC g g PIPC Cmax g g ml g g ml g g ml T T T PIPC g g T Ccr ml min AUCCmax PIPC

More information

アクテムラインタビューフォーム

アクテムラインタビューフォーム 2009 2 6 876399 IF 1998 9 FAX 80mg 1 4mL 80mg 200mg 1 10mL200mg 400mg 1 20mL400mg JAN TocilizumabGenetical RecombinationJAN 200mg 80400mg 2007 9 10 2008 4 16 2007 12 21 2008 6 13 2005 6 13 2008 6 13 2009

More information

untitled

untitled 1.4 特 許 状 況 - 1 - - 2 - 1.5 起 原 又 は 発 見 の 経 緯 及 び 開 発 の 経 緯 FCT CT RH ... 1.5-1... 1.5-1... 1.5-1... 1.5-1... 1.5-2... 1.5-2... 1.5-2... 1.5-3...1.5-4... 1.5-5 i 10mg FCT 1 1 6 15 5mg CT 1 1 2 6 4mg CT

More information

溶血性尿毒症症候群 ver 最終.pptx

溶血性尿毒症症候群 ver 最終.pptx Hemolytic uremic syndrome(hus) ver0130525 (HUS), Stx VT 3 3 1. ( Hb10g/dl ) 2. ( 10 /µl ) 3. ( 97.5 ) 1.5 ) (HUS) D+HUS D-HUS(aHUS) HUS ahus ( 6 HUS ( ) HUS HUS ahus O-157 9-30 HUS 15 80 5 5 10 2-3 (O-157

More information

Microsoft Word - 表紙資料2-4

Microsoft Word - 表紙資料2-4 (1) / 130 g 25 g 520% 170 g 30 g 560% 70 mg 600 mg 11.6% 0 10.5 mg 0% (1) (2) / 50100 g 25 g 200400% 50100 g 30 g 167333% 5001000 mg 600 mg 83167% 1020 mg 10.5 mg 95190% (2) / (1) 45.6 g 30 g 152% (2)

More information

untitled

untitled -- -- -3- % % % 6% % % 9 66 95 96 35 9 6 6 9 9 5 77 6 6 5 3 9 5 9 9 55 6 5 9 5 59 () 3 5 6 7 5 7 5 5 6 6 7 77 69 39 3 6 3 7 % % % 6% % % (: ) 6 65 79 7 3 36 33 9 9 5 6 7 3 5 3 -- 3 5 6 76 7 77 3 9 6 5

More information

untitled

untitled NO. 2007 10 10 34 10 10 0570-058-669 http://www.i-nouryoku.com/index.html (40 ) () 1 NO. 2007 10 10 2.2 2.2 130 70 20 80 30 () () 9 10 () 78 8 9 () 2 NO. 2007 10 10 4 7 3 NO. 2007 10 10 40 20 50 2 4 NO.

More information

表1.eps

表1.eps Vol.1 C ontents 1 2 cell-free EMBO J Proc. Natl. Acad. Sci. USA NatureEMBO J 3 RNA NatureEMBO J Nature EMBO J 4 5 HCV HCV HCV HCV RNA HCV in situ 6 7 8 Nat Struct Mol Biol J Biol Chem Nat Commun J Virol

More information

( ) ver.2015_01 2

( ) ver.2015_01 2 1 1.1 1.2 1.3 2 ( ) 2.1 2.2 2.3 2.4 3 4 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 4.9 5 5.1 5.2 5.3 5.4 6 6.1 6.2 6.3 7 7.1 7.2 7.3 8 ver.2015_01 2 1 1.1 1.2 1.3 ver.2015_01 3 2 2.1 2.2 2.3 ver.2015_01 4 2.4 ver.2015_01

More information

本文/一般演題_吉田

本文/一般演題_吉田 184 quality of lifeqol mmhg Hb gdl CA Uml Niveau Hb Hb gdl RCC CT MRI T 185 CT A B MRI A:T B:T Douglas red spot S ml RCC 186 A B mg CAUml S MRI A B 187 188 S mg Sampson JA. Intestinal adenomas of endometriosis

More information

表 1 入院時検査所見 11,500L 471 L 17.0 gdl.3 L ph 7.49 PaCO 37.8 mmhg PaO 67.4 mmhg HCO 3.6 meql B E 1. meql 141 meql K 3.9 meql Cl 108 meql Ca 8.4 mgdl P 4.5

表 1 入院時検査所見 11,500L 471 L 17.0 gdl.3 L ph 7.49 PaCO 37.8 mmhg PaO 67.4 mmhg HCO 3.6 meql B E 1. meql 141 meql K 3.9 meql Cl 108 meql Ca 8.4 mgdl P 4.5 Ⅰ. 臨床編 A. 特殊な病態における輸液 1 新生児 未熟児における輸液 実践編症例検討 症例の経過と実際の輸液療法 症例 ❶ 0 主訴 分娩歴 38 4,110 g.4 SD 47.5 cm0.5 SD 3.5 cm0.5 SD 8 1 9 5 現病歴 35 mgdl 60 0 mgdl 入院時現症 150 50 37. 503 mmhg SpO 98FiO 0.1 入院時検査所見 33 mgdl

More information

マニュアル第4版表紙PDF

マニュアル第4版表紙PDF 5 2004 4 1 5 2004 1968 1993 1994 1996 1998 2001 2004 3 I 1 1 2 2 3 12 4 24 5 48 6 59 7 65 8. 68 9 72 10 76 11 80 12 82 13 84 14 88 15 98 16. 106 17. (AIDS) 108 18 113 19 117 20 119 21 TPN 122 22 125 23.

More information

- 1 - A B C D E or or D or or d - 2 - A p18 P19 P21-3 - - 4 - B 2001 P21 P18 P19-5 - - 6 - C P21-7 - - 8 - D P21-9 - P16-10 - E - 11 - RT-PCR - 12 - P16-13 - P21-14 - P16-15 - - 16 - - 17 - Yes No Yes

More information

untitled

untitled DiBartola SP DiBartola SP 1987 Elliott Elliott J 1998 Elliott J 2000 Elliott J 2003 Part 1 24 0.75 70 1.3 1.3 2.0 1/2 2 6 1/2 22 18 Part 2003 Dr Chew 1 2 2 3 Part Cre Cre 1 Part Cre 2% 0.1ml/kg 0.3ml/kg

More information

4. 5.

4. 5. 1. 2. 20 3. 4. 5. ) N ) 6. ) 7. 8. JA 1. 30 CO2 18 2. 20 3. 4. 5. 5.1 cm 5.2 5.2.1 1 17kg 119kg11 5.2.2 60 750 2 2 5.2.3 30m 5.2.4 3 200g 6. 1 500 200 3 2 16 600 21 /10067kg/198kg10037 2025 3 4 3 3 6 102

More information

製品案内 価格表 2014/4/1

製品案内 価格表 2014/4/1 4 (17) 3 43 5/20370/ 231(504,150) 11 12 10 14-16 10 3 100 17 100kg 5-6 3 13 3 18 18 # # # # #$$ %&$ ' ()* +,-% ' #). +,-%'% / ' # # #$ %&&&'( %)* +'(#$ #$ %&&&'( ++,-). +'(#$ #$ /'( + /0)- +'(#$ %&&&'(

More information

3.ごみの減量方法.PDF

3.ごみの減量方法.PDF - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - ( 100 ( 100 - 13-123,550,846 111,195,762 92,663,135 ( 12 25 37 49.2 16 33 49 65.6 15 30 44 59.0 2.5kg) ( 5kg) ( 7.5kg) ( k ( 123,550,846 111,195,762 92,663,135 (

More information

16 41 17 22 12 10

16 41 17 22 12 10 1914 11 1897 99 16 41 17 22 12 10 11 10 18 11 2618 12 22 28 15 1912 13 191516 2,930 1914 5,100 43 1.25 11 14 25 34364511 7.54 191420 434849 72 191536 1739 17 1918 1915 60 1913 70 10 10 10 99.5 1898 19034.17.6

More information

indd

indd Molecular Targeted Therapy for Lung Cancer from a Pharmaceutical Point of Viewe Naho SASAKI epidermal growth factor receptor tyrosine kinase inhibitor :EGFR-TKI vascular endothelial growth factor:vegf

More information

1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b)

1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b) 2010.1.13 1) 4) 2 18 1) 1 2 3 4 2) 1 2 85 3 3) 1 metabolizer 2 metabolizer 3 metabolizer 4 metabolizer 4) CYP 1 2 metabolizer 3 metabolizer 4 5 6 4 7 2 5 (PPI) 1 2 PPI 2 3 2 3 3 3 3 PPI 3 1 ph 4 5 1) 5)

More information

評価結果報告書の概要版(平成20年度)

評価結果報告書の概要版(平成20年度) 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76

More information

20-121

20-121 20 121 150 1 20 121 1 HbA1C 1 2 2 HbA1C 3 2 4 5 HbA1C 1 HbA1C -NH2 -CHO HbA1C 1 1 HbA1C HbA1C HbA1C HbA1C HbA1C 120 HbA1C HbA1C 1 2 2 HbA1C 120 10 10 10 3 β β 1 1 GAD ICA 2 4 HbA1C 2 1 2 5 2 20 121 150

More information

油汚染鳥救護のガイドライン

油汚染鳥救護のガイドライン 9 1 1300 12 12 11 NGO 18 419 1804 NGO 19 3 1 1 ( ) 5 ( ) 11 ( ) 13 () 13 () 14 () 14 () 16 () 18 () 23 [ ] ( ) 25 25 26 26 33 34 35 [ ] 36 ( ) 37 () 39 () 39 () 40 () 42 () 42 2 () () () () 45 48 50 50

More information

小児感染免疫第25巻第2号

小児感染免疫第25巻第2号 Vol. 25No. 2145 1,2 1 1 1 1 2 2 2 TFLX 9 TFLX 450 mg16.6 mgkg TFLX 30 kg TFLX 2009 10 TFLX 1 1 2 3,4 TFLX 9 22 6 18 19 TFLX 450 mg150 mg 1 1 1 3 16.6 mgkg 20 20 0 21 3 135.0 cm0.1 S.D. 27.0 kg0.8 S.D.

More information

C VECS C F M kg A E W kg I A R. R. Gkg MGD MGD MGD MGD SPKMGD MGD MGD SPK SPK MGD MMP MMP MMP kg mmhg Intrascleral prosthesis : ISPISP ISP ISP ISP ISP ISP ISP ISP ISP mm mm ISP mm min mm min ISP mm min

More information

肝臓病教室201207v2配布用.pptx

肝臓病教室201207v2配布用.pptx 24 7 28 5 C C C C 11 1 vs 2 vs 1 0 1 600-1000mg 3-5/ 24,48 2448 12 1 1500-2250mg 6-9/ () 1 600-1000mg 3-5/ 0 24 88.1% 0 20 40 60 80 100 C ALT, GPT 30 34.4% ALT, GPT 0 20 40 60 80 100 2 , 2 3 1 1-100% 0

More information

untitled

untitled 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 1 1 1 ICHMedDRA/J ver. 10.0Preferred Term 30 ICH MedDRA/Jver.11.1 EU ICHICH MedDRA 0325001 0325032 ICH MedDRA/J PT LLT MedDRA

More information

NIHSS score p NIHSS score p149 4 p g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml

NIHSS score p NIHSS score p149 4 p g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml NIHSS score14 1 400 1 p149 1 25 20 NIHSS score14 15 10 5 2 p149 4 p151 0 0.8 g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml 1 2 148 149 3 2 3 A B C 4 D 2 A B C A C 1 Ogata T et al J Neurol Sci 272 83 86 2008

More information

橡DI月報178.PDF

橡DI月報178.PDF 2002.5.10. DI 22-2668 HCV HCV 1 1 375mg/ 13 60mg 20mg 1 20mg 1 750mg 1 400mg 3 1 2 7 IAB IAB IAB IAB IAB HIV ( ) HIV CYP3A4 HIV ( ) CYP3A4 WBC CK CK 1) 2) Torsades de Pointes K ) ALT AST -GTP CYP2C9 CYP2C19

More information

エクラー軟膏0.3%、エクラークリーム0.3%、エクラーローション0.3%_IF

エクラー軟膏0.3%、エクラークリーム0.3%、エクラーローション0.3%_IF 2005 1 872646 IF 1998 9 1g 3mg(0.3%) Deprodone Propionate 2003227 200374 1997415( ) 1998316( ) F A X 2003 7 1992 3 17 1997 10 9 1992 5 22 1997 12 19 IF 2005 4 IF 1. MR 63 2 IF 10 3 IF 2. IF IF IF 3. IF

More information

グリセオール注インタビューフォーム

グリセオール注インタビューフォーム 2006 8 3 873999 871319 IF 1998 9 FAX 1 200mL 300mL 500mL 20g 30g 50g 10g 15g 25g 1.8g 2.7g 4.5g 0.9W/V 200mL500mL 1979 3 13 2004 7 9 1979 5 15 2006 8 300mL 1979 3 13 2004 7 9 1982 11 1 IF 1 MR 63 IF 10

More information

( ) M5, 2007 67.3 67.3 N=97 34.9 34.9 N=97 PBL- PBL- () PBL- PBL- 48.1 48.1 N=97 86.9 86.9 N=97 36.2 36.2 N=97 55.6 55.6 N=97 M5, 2007 N=101 CBT r 0.146 PBL- 4%2% 7% 5% 2% 5% 9% 66% N=82 : 1020 : 301 :

More information

PJta_h1h4_0329.ai

PJta_h1h4_0329.ai 0120-119-110 1-2-1 100-8050 http://www.tokiomarine-nichido.co.jp/ 24365 0120-691-300 98 http://www.tokiomarine-nichido.co.jp/ 201071 19 P.37 P.816 P.17 P.1819 contents 1 2 3 4 5 6 1 2 3 4 http://www.tokiomarine-nichido.co.jp/

More information

−ÈŁÛ05/‚æ4‘Í

−ÈŁÛ05/‚æ4‘Í CONTENTS 1. 50 2. 51 3. 52 52. 6 1 6 2 6 3 65 65 5. 66 6. 67 1 67 2 67 3 68 7. 69 8. 69 1 69 2 69 3 70 70 9. 71 9 1 50 2 51 52 3 53 5 55 56 57 58 59 60 61 62 63 1 2 6 3 65 5 66 6 1 2 67 3 68 7 8 1 2 69

More information

24_5章_01f

24_5章_01f CONTENTS p08 1 2 3 4 p14 p20 p24 p28 p40 03 04 05 4527,575 9 405,849 0.1 4,908 9405,849 17 790,361 74 3,331,365 6 243,400 34 1,554,738 51 2,318,680 161,853 122,460 9 410,863 163,253 3121,444 0.15,830 24

More information

untitled

untitled T O N E G U N 2012 S H I N K I N E R S U L O C S I D B A N K 1. 2. 3. CONTENTS 1. 2. 1. 2. 3. 4. 5. 02 03 04 05 17, 216 84362 1,63323 516 225 17 06 07 1,385 46 1 42 31 3.3% 2.2% 67.4% 08 09 10 1 3 2 1

More information